UB Paderborn / Katalog / Suche / in CDI

Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer

European urology, 2019-04, Vol.75 (4), p.667-675

2019

Volltextzugriff (PDF)

BRCA2 , ATM , and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression

Clinical cancer research, 2021-03, Vol.27 (6), p.1650-1662

2021

Volltextzugriff (PDF)

Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer

Clinical cancer research, 2020-03, Vol.26 (5), p.1114-1125

2020

Volltextzugriff (PDF)

Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer

European urology, 2020-12, Vol.78 (6), p.834-844

2020

Volltextzugriff (PDF)

Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition

Clinical cancer research, 2021-08, Vol.27 (16), p.4610-4623

2021

Volltextzugriff (PDF)

Biallelic tumour suppressor loss and DNA repair defects in de novo small‐cell prostate carcinoma

The Journal of pathology, 2018-10, Vol.246 (2), p.244-253

2018

Volltextzugriff (PDF)

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

Nature communications, 2024-02, Vol.15 (1), p.1828-1828, Article 1828

2024

Volltextzugriff (PDF)

A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes

NPJ precision oncology, 2023-03, Vol.7 (1), p.27-27, Article 27

2023

Volltextzugriff (PDF)

Technical and biological constraints on ctDNA-based genotyping

Trends in cancer, 2021-11, Vol.7 (11), p.995-1009

2021

Volltextzugriff (PDF)

Circulating tumor DNA fraction (ctDNA%) to independently predict for clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5049-5049

2021

Volltextzugriff (PDF)

Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer

Nature (London), 2022-08, Vol.608 (7921), p.199-208

2022

Volltextzugriff (PDF)

Abstract 3541: Biallelic alterations in BRCA2, ATM, or CDK12 in metastatic prostate cancer via circulating tumor DNA

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.3541-3541

2020

Volltextzugriff (PDF)

Machine-learning to predict utility of circulating tumor DNA (ctDNA) for somatic genotyping

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.232-232

2023

Volltextzugriff (PDF)

Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Clinical cancer research, 2023-08, Vol.29 (15), p.2835-2844

2023

Volltextzugriff (PDF)

The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

Cancer research (Chicago, Ill.), 2022-11, Vol.82 (21), p.3888-3902

2022

Volltextzugriff (PDF)

Detection of clinically-actionable alterations as hallmarks of de novo small cell prostate cancer

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e17072-e17072

2018

Volltextzugriff (PDF)

Biallelic loss of TP53, PTEN, and RB1 in association to aggressive clinical features and poor outcomes in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5055-5055

2022

Volltextzugriff (PDF)

Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer

Urologic oncology, 2019-11, Vol.37 (11), p.826-836

2019

Volltextzugriff (PDF)

Genetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair

American Society of Clinical Oncology educational book, 2023-05, Vol.43 (43), p.e390384-e390384

2023

Volltextzugriff (PDF)

Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) using circulating cell-free tumor DNA (ctDNA)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.260-260

2018

Volltextzugriff (PDF)

Identification, incidence and clinical outcomes of patients (pts) with hypermutated prostate cancer (PC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.5072-5072

2019

Volltextzugriff (PDF)

Abstract A24: Identifying the genomic and clinical features of AKT1/PIK3CA mutant metastatic prostate cancer using circulating tumor DNA

Clinical cancer research, 2020-06, Vol.26 (11_Supplement), p.A24-A24

2020

Volltextzugriff (PDF)

Somatic Features of Response and Relapse in Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy

European urology oncology, 2022-12, Vol.5 (6), p.677-686

2022

Volltextzugriff (PDF)

Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer

Urologic oncology, 2019-09, Vol.37 (9), p.573.e19-573.e29

2019

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer

BRCA2 , ATM , and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression

Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer

Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer

Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition

Biallelic tumour suppressor loss and DNA repair defects in de novo small‐cell prostate carcinoma

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes

Technical and biological constraints on ctDNA-based genotyping

Circulating tumor DNA fraction (ctDNA%) to independently predict for clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer

Abstract 3541: Biallelic alterations in BRCA2, ATM, or CDK12 in metastatic prostate cancer via circulating tumor DNA

Machine-learning to predict utility of circulating tumor DNA (ctDNA) for somatic genotyping

Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

Detection of clinically-actionable alterations as hallmarks of de novo small cell prostate cancer

Biallelic loss of TP53, PTEN, and RB1 in association to aggressive clinical features and poor outcomes in metastatic castration-resistant prostate cancer (mCRPC)

Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer

Genetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair

Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) using circulating cell-free tumor DNA (ctDNA)

Identification, incidence and clinical outcomes of patients (pts) with hypermutated prostate cancer (PC)

Abstract A24: Identifying the genomic and clinical features of AKT1/PIK3CA mutant metastatic prostate cancer using circulating tumor DNA

Somatic Features of Response and Relapse in Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy

Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping

Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer

Suchergebnisse filtern